Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intranasal granisetron moves forward

This article was originally published in Scrip

Executive Summary

Japan's Shin Nippon Biomedical Laboratories (SNBL) has begun a US Phase II trial with a novel intranasal formulation of the anti-emetic granisetron. The self-dosed product is being developed by the firm's wholly owned Translational Research subsidiary and is delivered through a device developed by Bioactis, another SNBL company. The aim is to overcome problems with oral dosing in chemotherapy patients with nausea and vomiting and the pain and inconvenience of injection. Phase I data showed rapid absorption, with 70% of the maximum blood concentration achieved within 10 minutes, high bioavailability and no irritation, SNBL said. It is also developing intranasal formulations of other drugs such as morphine, sumatriptan and insulin and plans to seek licensing or alliance deals for granisetron after the Phase II results.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030926

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel